Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 81, Issue 5, Pages 761-767Publisher
WILEY
DOI: 10.1038/sj.clpt.6100167
Keywords
-
Categories
Ask authors/readers for more resources
Dipeptidyl peptidase-4 ( DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. 1 DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. 1 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available